Profound Medical Q3 revenue beats estimates

Profound Medical

13/11/2025 21:31

Overview

Profound Medical Q3 revenue up 87% yr/yr, beating analyst expectations

Gross margin increased 1,119 basis points to 74.3% in Q3-2025

Company reported a net loss of $8 mln, improved from last year

Outlook

Profound Medical expects to reach at least 75 TULSA-PRO installs by year-end

Result Drivers

SALES PIPELINE - Profound's growing TULSA-PRO sales pipeline contributed to revenue growth

MANUFACTURING EFFICIENCY - Gross margin expansion attributed to higher manufacturing efficiency

STRATEGIC AGREEMENTS - New distribution agreements expected to support growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$5.30 mln
$4.72 mln (4 Analysts)
Q3 EPS
-$0.26
Q3 Net Income
-$8 mln
Q3 Operating Expenses
$12.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Press Release: ID:nGNX5qK5bW

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)